BRPI0512042A - composição imunogênica, vacina, métodos de evitar infecção e/ou doença por hpv, de produzir uma composição imunogênica e de prevenir ou tratar infecção e/ou doença por hpv - Google Patents
composição imunogênica, vacina, métodos de evitar infecção e/ou doença por hpv, de produzir uma composição imunogênica e de prevenir ou tratar infecção e/ou doença por hpvInfo
- Publication number
- BRPI0512042A BRPI0512042A BRPI0512042-0A BRPI0512042A BRPI0512042A BR PI0512042 A BRPI0512042 A BR PI0512042A BR PI0512042 A BRPI0512042 A BR PI0512042A BR PI0512042 A BRPI0512042 A BR PI0512042A
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- immunogenic composition
- preventing
- hpv infection
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
COMPOSIçãO IMUNOGêNICA, VACINA, MéTODOS DE EVITAR INFECçãO E/OU DOENçA POR HPV, DE PRODUZIR UMA COMPOSIçãO IMUNOGêNICA E DE PREVENIR OU TRATAR INFECçãO E/OU DOENçA POR HPV Uma composição imunogênica e métodos para produzir dita composição, a composição compreendendo VLPs de HPV 16 e 18 e pelo menos um outro tipo de câncer HPV, o outro tipo de câncer sendo selecionado da lista consistindo de I-IPV tipos 31, 45 e 52, em que a dose do VLP do pelo menos um outro tipo de câncer é reduzida àquela do HPV 16 ou 18.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0413510.9A GB0413510D0 (en) | 2004-06-16 | 2004-06-16 | Vaccine |
| US11/114,301 US20050287161A1 (en) | 2002-12-20 | 2005-04-26 | Vaccine |
| PCT/EP2005/006461 WO2005123125A1 (en) | 2004-06-16 | 2005-06-14 | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0512042A true BRPI0512042A (pt) | 2008-02-06 |
| BRPI0512042B1 BRPI0512042B1 (pt) | 2019-01-22 |
| BRPI0512042B8 BRPI0512042B8 (pt) | 2021-05-25 |
Family
ID=35160037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0512042A BRPI0512042B8 (pt) | 2004-06-16 | 2005-06-14 | composição imunogênica, vacina, uso de uma composição ou vacina, método para produzir uma composição imunogênica, e, uso de vlps ou capsômeros de hpv 16 e 18 com vlps ou capsômeros de pelo menos um outro hpv do tipo causador de câncer |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1758609B1 (pt) |
| JP (1) | JP2008502633A (pt) |
| KR (1) | KR20070029254A (pt) |
| AR (1) | AR049354A1 (pt) |
| AU (1) | AU2005253723B2 (pt) |
| BR (1) | BRPI0512042B8 (pt) |
| CA (1) | CA2566620C (pt) |
| FR (2) | FR15C0082I2 (pt) |
| IL (1) | IL179138A0 (pt) |
| LU (3) | LU92899I2 (pt) |
| MA (1) | MA28692B1 (pt) |
| MX (1) | MXPA06014515A (pt) |
| NO (1) | NO20070195L (pt) |
| PE (1) | PE20060434A1 (pt) |
| PL (1) | PL1758609T3 (pt) |
| RU (1) | RU2420313C2 (pt) |
| SG (1) | SG153837A1 (pt) |
| WO (1) | WO2005123125A1 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080005583A (ko) * | 2005-04-26 | 2008-01-14 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
| SI2318042T1 (sl) * | 2008-07-31 | 2014-12-31 | Glaxosmithkline Biologicals S.A. | Cepivo proti HPV |
| WO2010147268A1 (ko) * | 2009-06-19 | 2010-12-23 | 아이진 주식회사 | 자궁경부암 백신 |
| JP5964298B2 (ja) * | 2010-07-15 | 2016-08-03 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | ヒトパピローマウイルスｅ７抗原組成物およびその使用 |
| SG11201501623PA (en) | 2012-10-30 | 2015-05-28 | Redvax Gmbh | Recombinant particle based vaccines against human cytomegalovirus infection |
| EP3209676A4 (en) * | 2014-10-24 | 2018-03-28 | Hpvvax, Llc | Cancer and skin lesion treatment |
| CN107188966B (zh) | 2016-03-15 | 2020-03-31 | 中国医学科学院基础医学研究所 | 一种乳头瘤病毒嵌合蛋白及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9921147D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| US6908613B2 (en) * | 2000-06-21 | 2005-06-21 | Medimmune, Inc. | Chimeric human papillomavirus (HPV) L1 molecules and uses therefor |
| GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
| GB0206359D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0206360D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| ATE503492T1 (de) * | 2002-12-20 | 2011-04-15 | Glaxosmithkline Biolog Sa | Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 |
-
2005
- 2005-06-14 MX MXPA06014515A patent/MXPA06014515A/es active IP Right Grant
- 2005-06-14 PE PE2005000677A patent/PE20060434A1/es not_active Application Discontinuation
- 2005-06-14 CA CA2566620A patent/CA2566620C/en not_active Expired - Lifetime
- 2005-06-14 PL PL05757953T patent/PL1758609T3/pl unknown
- 2005-06-14 AR ARP050102434A patent/AR049354A1/es not_active Application Discontinuation
- 2005-06-14 JP JP2007515878A patent/JP2008502633A/ja active Pending
- 2005-06-14 KR KR1020077001065A patent/KR20070029254A/ko not_active Ceased
- 2005-06-14 AU AU2005253723A patent/AU2005253723B2/en active Active
- 2005-06-14 SG SG200904200-3A patent/SG153837A1/en unknown
- 2005-06-14 RU RU2006143804/10A patent/RU2420313C2/ru active
- 2005-06-14 BR BRPI0512042A patent/BRPI0512042B8/pt not_active IP Right Cessation
- 2005-06-14 WO PCT/EP2005/006461 patent/WO2005123125A1/en not_active Ceased
- 2005-06-14 EP EP05757953A patent/EP1758609B1/en not_active Expired - Lifetime
-
2006
- 2006-11-09 IL IL179138A patent/IL179138A0/en unknown
- 2006-12-28 MA MA29576A patent/MA28692B1/fr unknown
-
2007
- 2007-01-11 NO NO20070195A patent/NO20070195L/no not_active Application Discontinuation
-
2015
- 2015-12-04 FR FR15C0082C patent/FR15C0082I2/fr active Active
- 2015-12-04 FR FR15C0084C patent/FR15C0084I2/fr active Active
- 2015-12-08 LU LU92899C patent/LU92899I2/xx unknown
- 2015-12-08 LU LU92898C patent/LU92898I2/xx unknown
- 2015-12-08 LU LU92900C patent/LU92900I2/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2006143804A (ru) | 2008-08-20 |
| FR15C0082I2 (fr) | 2016-10-28 |
| AU2005253723B2 (en) | 2011-01-20 |
| JP2008502633A (ja) | 2008-01-31 |
| LU92898I2 (fr) | 2016-03-08 |
| FR15C0084I2 (fr) | 2016-10-28 |
| FR15C0082I1 (fr) | 2016-01-08 |
| CA2566620C (en) | 2014-03-11 |
| EP1758609B1 (en) | 2012-10-03 |
| MXPA06014515A (es) | 2007-03-23 |
| KR20070029254A (ko) | 2007-03-13 |
| BRPI0512042B8 (pt) | 2021-05-25 |
| AU2005253723A1 (en) | 2005-12-29 |
| NO20070195L (no) | 2007-01-15 |
| PL1758609T3 (pl) | 2013-02-28 |
| AR049354A1 (es) | 2006-07-19 |
| LU92899I2 (fr) | 2016-03-08 |
| IL179138A0 (en) | 2007-03-08 |
| EP1758609A1 (en) | 2007-03-07 |
| LU92900I2 (fr) | 2016-03-08 |
| RU2420313C2 (ru) | 2011-06-10 |
| FR15C0084I1 (pt) | 2016-01-08 |
| PE20060434A1 (es) | 2006-06-08 |
| MA28692B1 (fr) | 2007-06-01 |
| WO2005123125A1 (en) | 2005-12-29 |
| CA2566620A1 (en) | 2005-12-29 |
| SG153837A1 (en) | 2009-07-29 |
| BRPI0512042B1 (pt) | 2019-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6531463A2 (es) | Combinaciones de un inhibidor de pi3k y un inhibidor de mek | |
| EA201000914A1 (ru) | Новые терапевтические подходы в лечении смт и связанных с ней расстройств | |
| MX2018010586A (es) | Nanovacuna de activacion de "sting" para inmunoterapia. | |
| MY201105A (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
| NO20053782L (no) | Behandling av kreft med 2-deoksyglukose | |
| BR112012004806B8 (pt) | composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso | |
| PA8637301A1 (es) | Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa | |
| CL2008003822A1 (es) | Compuestos derivados de n1-(2-tiazolil)-1,2-dicarboxamida pirrolidina; procedimiento de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de enfermedades mejoradas por la inhibicion de la fosfatidilinositol-3-cinasa, como el cancer. | |
| GEP20146134B (en) | Inhibitors of hepatitis c virus replication | |
| EA200971026A1 (ru) | Новые макроциклические ингибиторы репликации вируса гепатита с | |
| CY1115690T1 (el) | Συνθεσεις βασιζομενες σε arthrospirα και χρησεις αυτων | |
| BRPI0720551A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
| AR071003A1 (es) | Farmaco contra cancer de higado | |
| EA201690069A1 (ru) | Применение высоких доз придопидина для лечения болезни хантингтона | |
| AR067903A1 (es) | Metodo para tratar la depresion mediada por estres | |
| AR083395A1 (es) | Derivado peptidico nmu (neuromedina u) con elevado efecto anorectico | |
| BRPI0908124A2 (pt) | Composto, ativador de glucoquinase, composição farmacêutica, uso de um composto ou sal farmacologicamente aceitavél do mesmo, e, métodos de ativação da glucoquinase, e para tratar e/ou prevenir uma doença | |
| BR112012008325A2 (pt) | N-4 ( - ( ( 3- ( 2 - amino-4 pirimidinil) -2 -piridinil) oxi) fenil) -4- (4-metil-2-tienil) -1- ftalazinamina para uso no tratamento de câncer resistente a agente antimitótico | |
| AR062401A1 (es) | Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis | |
| BR112022021957A2 (pt) | Imidazopirimidinas como moduladores de il -17 | |
| CL2015001086A1 (es) | Combinación farmacéutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas | |
| WO2022192594A3 (en) | Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease | |
| BRPI0512042A (pt) | composição imunogênica, vacina, métodos de evitar infecção e/ou doença por hpv, de produzir uma composição imunogênica e de prevenir ou tratar infecção e/ou doença por hpv | |
| CY1112063T1 (el) | Παραγοντας κατα του ιου της νοσου του αφθωδους πυρετου για ζωα που ανηκουν στην οικογενεια των συιδων ή των προβατων, και μεθοδος για προληψη ή αντιμετωπιση της νοσου του αφθωδους πυρετου σε ζωα που ανηκουν στην οικογενεια των συιδων ή των προβατων |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/01/2019, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/06/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B15V | Prolongation of time limit allowed | ||
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 14/06/2025. |